Navigation Links
Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System

Key words: NK2 • GPCR receptor binding assay LEADseeker SPA Imaging Beads


Neurokinins, also known as tackykinins, are a family of small neuropeptides. Members of this family include peptides, substance P (SP), neurokinin A (NKA), neurokinin B (NKB), and the recently discovered hemokinin-1 (1). Neurokinins are widely distributed throughout the central and peripheral nervous system where they act via G protein-coupled receptors (NK1, NK2, and NK3 receptors) as neurotransmitters and neuromodulators. They are also considered key mediators in the communication between neurons (particularly sensory neurons) and effector cells (e.g., smooth muscle, glands, and immune cells), a role that is significant to the pathophysiology of a wide variety of diseases including gastrointestinal disorders, emesis, chronic pain, depression, and asthma (2). Members of the neurokinin family favor specific receptors. SP, for instance, shows greatest affinity for NK1 receptors, NKA for NK2, and NKB for NK3 (3). Of these receptors, NK2 receptors are thought to be expressed mainly on smooth muscle cells (4). Additionally, NKA and its truncated form, NKA (4-10), are potent contractors of human colon circular muscle, an action mediated exclusively via NK2 receptors (5).

This application note describes a 384-well NK2 neuropeptide receptor binding assay developed using LEADseeker™ Multimodality Imaging System. The miniaturized assay is robust, achieving a Z’ value of 0.62 and a stability window of 18 h. These factors make the assay suitable for adaptation to automated screening formats.


Materials
Products used
LEADseeker Multimodality Imaging System 18-1140-71

Wheat Germ Agglutinin (WGA)-PEI Type A RPNQ0287
PS S PA Imaging Beads

(2-[125I]iodohistidyl1) Neurokinin A ([125I]Substance K) IM168


Other materials required
Human recombinant NK2 receptor membrane preparation (Euroscreen)

[β-Ala8]-Neurokinin A fragment (4–10) (Sigma)

Costar™ solid white 384-well microplate (Corning)

Protease-free BSA (Sigma)

Buffer: 50 mM Tris pH 7.4
5 mM MgCl2
2 mM EDTA
0.2% BSA (w/v)

GraphPad Prism™ software v4.0 (GraphPad Software)


Protocol
Human recombinant NK2 receptor membrane preparation was used in conjunction with [125I]NKA ligand and WGA-PEI Type A PS SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 5 µM NKA (4–10). The standard assay format was as follows:

1) Reagents were added in the following order: buffer, unlabeled ligand (NSB wells), labeled ligand, membrane, and bead. Total assay volume was 50 µl.

2) Each well contained 10 µl of 0.85 nM [125I]NKA (final concentration 0.17 nM) unless otherwise stated, 2.5 µg of membrane, and 250 µg of beads. Membrane and beads were added in 10 µl volumes.

3) NSB wells contained 20 µl of 13 µM NKA (4–10) (final concentration 5 µM) in addition to the above.

4) Plates were sealed and incubated in darkness for 5 h at room temperature (20–25 °C).

5) Following incubation, plates were imaged on LEADseeker Multimodality Imaging System for 5 min using quasi-coincident averaging and 3 ×3 binning.


Results
Kd determination
Saturation binding was performed with dilutions of [125I]NKA to give a range of concentrations from 0.01 to 1.34 nM in the wells. Figure 1 shows the saturation curve, which was fitted using non-linear regression with the data analysis software package GraphPad Prism v4.0. A Kd value of 0.4 nM (95% confidence intervals 0.3–0.4 nM) was estimated directly from the curve.

IC50 determination
Competitive binding of 0.17 nM [125I]NKA with unlabeled NKA (4–10) was assessed and the IC50 calculated as shown in Figure 2. Final concentrations in the well were 0.002–10 000 nM. Over two experiments, the mean NKA (4–10) IC50 value was determined to be 18.9 nM (95% confidence interval range 13.7–26.1 nM) and mean Ki value was 13.3 nM (95% confidence intervals 9.6–18.3 nM).

Time course
In addition, a time course was performed using standard reagent concentrations detailed in the protocol with an increased incubation time of 18 h. The assay appeared to be stable for the full 18 h as shown in Figure 3.

Z’ analysis
Finally, a Z’ analysis was performed using 42 replicate values for "total" and NSB wells (6). The Z’ value indicated by Figure 4 is 0.62, which was well within the acceptable Z’ value range (0.5–1.0) and confirmed the robustness of the assay.


References
1. Patacchini, R. et al. Trends in Pharmacological Sciences 25, 1–3 (2004).

2. Longmore, J. et al. Canadian Journal Physiology and Pharmacology 75, 612–621 (1997).

3. Regoli, D. et al. Pharmacological Review 46, 551–599 (1994).

4. Lecci, A. et al. British Journal Pharmacology 141, 1249–1263 (2004).

5. Giuliani, S. et al. European Journal Pharmacology 203, 365–370 (1991).

6. Zhang, J. et al. Journal Biomolecular Screening 4 (2), 67–73 (1999).



back to top
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
2. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
3. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
4. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
5. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
6. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
7. Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System
8. Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
9. Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.
10. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2016)... ... February 09, 2016 , ... Tunnell Consulting, Inc. announced that Frédéric Lefebvre ... will focus on acquiring new accounts and work closely with existing Tunnell clients throughout ... brings to our European clients more than 15 years of experience in the pharmaceutical ...
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/8/2016)... GUELPH, ON , Feb. 8, 2016 /PRNewswire/ - BIOREM ... nominated to the top ten finalists for clean technology companies ... are the top 10 companies listed on the TSX ... mining, oil & gas, clean technology & life ... formula with equal weighting given to return on investment, market ...
(Date:2/8/2016)... ... 2016 , ... Thomas J. Todorow has joined the University ... Corporate Services and the Chief Financial Officer at The Children’s Hospital of Philadelphia ... Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP and The ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces ... personality, Joey Fatone . Las Vegas , ... --> Las Vegas , where Joey appeared ... The new video ad was filmed at the Consumer Electronics Show ... the Wocket booth to meet and greet fans. ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
(Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
Breaking Biology News(10 mins):